Interaction Color Code
Clinical Bottom Line
Do not coadminister: Potential for reduced levels of sofosbuvir
Drug 1
Drug 1 dose
200 mg x 1
Drug 1 effect
Nevirapine AUC decreased 79%; Cmax decreased 20%; Cmin decreased 60%; half-life: decreased 66%
Drug 2
Drug 2 effect
Potential decrease in sofosbuvir and velpatasvir levels).
Clinical Effects
Potential loss of anti-HCV efficacy
Management
Use alternative agents
Import ID
609
